Listen on the go
    • Faculty & Disclosures
    Dr Kei Muro

    Aichi Cancer Center Hospital, Nagoya, Japan

    Dr Kei Muro, MD, PhD, is chief and director of the Department of Clinical Oncology and Outpatient Treatment Center at Aichi Cancer Center Hospital in Nagoya, Japan. read more

    He is an adjunct professor at Nagoya University Graduate School of Medicine and Tokyo University Graduate School of Medical Science, and is an adjunct and clinical professor at Nagoya City University Graduate School of Medical Science.

    Dr Muro graduated from the University of Tohoku Medical School in 1990 and completed his internal medicine training at the Iwaki Kyoritsu Hospital in 1993. He completed his residency in gastrointestinal oncology in the Digestive Endoscopy Division at the National Cancer Center Hospital East in 1997 and has been a staff doctor in the Gastrointestinal Oncology Division at the National Cancer Center Hospital since 1997. He was awarded his PhD in medical science from the Yokohama City University in 2021.

    Dr Muro is an executive board member of the Japanese Society of Medical Oncology and the Japanese Gastric Cancer Association. He is also a council member of the Japan Esophageal Society and the Japanese Cancer Association. He is a member of the American Society of Clinical Oncology and was a faculty member of the gastrointestinal tumours group at the European Society of Medical Oncology (2017–2021). He collaborates with the World Health Organization on the Japanese Gastric Cancer Committee. In terms of clinical trial activity, he is the chair of the gastrointestinal cancer group in the West Japan Oncology Group. He is also a reviewer for the Japanese Journal of Clinical Oncology and Esophagus. Furthermore, he was awarded the Nagoya International Cancer Treatment Symposium BMS Award in 2012 and was also awarded the Excellent Presentation Award from the Japan Society of Clinical Oncology in 2013. He is the author of more than 370 peer-reviewed publications.

    Dr Kei Muro discloses: Advisory board or panel fees from Amgen and AstraZeneca. Consultancy fees from Chugai and Ono. Grants/research support from Amgen, Astellas, Daiichi Sankyo, Eisai, Merck Serono, MSD, Novartis, Ono, Parexel International, Pfizer, Sanofi, Solasia Pharma and Taiho. Speaker’s bureau fees from Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Ono and Taiho.
    Dr Rachel Riechelmann

    AC Camargo Cancer Center, São Paulo, Brazil

    Prof. Rachel Riechelmann, MD, PhD, is a medical oncologist and clinical scientist specializing in colorectal and anal cancers and neuroendocrine tumours (NET). She is currently the director of the Clinical Oncology Department at the AC Camargo Cancer Center in São Paulo, Brazil, and also serves as the president of the Brazilian Gastrointestinal Tumors Group (GTG). read more

    She has published more than 125 articles in peer-reviewed journals and is editor of Methods and Biostatistics in Oncology: Understanding Clinical Research as an Applied Tool (Springer, 2018). Prof. Riechelmann is a member of two European Society of Medical Oncology scientific committees (colorectal and NET), the Latin American Society of GI Oncology (SLAGO) and the European Society of Neuroendocrine Tumors Advisory Board, and the chair of the Gastrointestinal LACOG (Latin American Cooperative Oncology Group). She is also actively involved in mentoring and teaching of young oncologists.

    Dr Rachel Riechelmann discloses: Advisory board/panel fees from AstraZeneca and Servier (both relationships terminated). Grants/Research Support from Bayer and Libbs.
    Dr Chiara Cremolini

    University of Pisa, Pisa, Italy

    Dr Chiara Cremolini, MD, PhD,  is an associate professor in medical oncology at the University of Pisa in Italy. read more

    Following an MD Degree in 2008, a Master of Science in Clinical Trials, and a Specialty in Medical Oncology at the University of Pisa, she gained her PhD in Clinical Pathophysiology.

    She is mainly committed to the clinical management of patients affected by gastrointestinal malignancies, and is involved in clinical and translational research projects in the field of colorectal oncology. She is responsible for the scientific activities of the Clinical Trials’ Office at the oncology unit at Santa Chiara Hospital in Pisa. She actively contributes to clinical trials run by the Gruppo Oncologico del Nord Ovest (GONO), an Italian foundation involved in the design and execution of clinical and translational studies of several solid malignancies. Dr Cremolini served as the scientific secretary of GONO between 2015 and 2021, and has been the president since 2021. She is a faculty member of European Society for Medical Oncology gastrointestinal tumour group, and has been particularly involved in trials investigating intensified chemotherapy regimens as upfront treatment of metastatic colorectal cancer patients.

    With regard to translational activities, she is mainly interested in the identification of molecular predictors of benefit from systemic treatments, and to this purpose has collaborated with numerous international institutions. She is author of more than 200 papers in the field of colorectal cancer.

    Dr Chiara Cremolini discloses: Advisory board or panel fees from Amgen, Bayer, Merck, Pierre Fabre and Servier. Consultancy fees from Bayer. Grants/Research Support from Bayer, Merck and Servier.
    Downloads

    View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:

    • Colorectal Cancer

    An Introduction to Colorectal Cancer

    Colorectal cancer (CRC) is the third leading cause of cancer death worldwide. The mainstay of treatment for advanced disease is chemotherapy combined with angiogenesis inhibitors and epidermal growth factor receptor (EGFR) inhibitors, but outcomes and toxicity are highly variable. Recent advances include combined small molecule/monoclonal antibody therapies for CRC with the V600E mutation in the BRAF gene for metastatic disease and immune checkpoint inhibition.

    Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.

    Colorectal Cancer Content

    Colorectal Cancer, Gastrointestinal Cancers
    Watch Time: 20 mins
    touchPANEL DISCUSSION
    Optimizing strategies for the treatment of colorectal cancer in the biomarker era
    CE/CME ACCREDITED Dr Kei Muro, Dr Chiara Cremolini, Dr Rachel Riechelmann Translations available:

    Dr Muro, Dr Cremolini and Dr Riechelmann discuss how biomarkers can guide treatment choices for patients with colorectal cancer.

    Learning objectives
    Learning Objectives
    • Choose appropriate first-line treatment for patients with CRC based on biomarker testing and clinical characteristics
    • Compare and contrast the available techniques for biomarker testing recommended for patients with CRC
    • Review the evidence for recent and emerging targeted therapy options for CRC
    Colorectal Cancer, Gastrointestinal Cancers
    Watch Time: 47 mins
    touchMDT
    How can HER2-targeted therapies be incorporated into the management of patients with CRC?
    CE/CME ACCREDITED Prof. Andrea Sartore-Bianchi, Dr Evgeny Yakirevich, Dr Kristen Ciombor, Dr Kelley Rone, Mr Scott Wilson

    Hear multidisciplinary team and patient perspectives on the management of HER2-positive colorectal cancer.

    Learning objectives
    Learning Objectives
    • Summarize how to test for HER2 amplifications in patients with CRC and how to interpret the results
    • Discuss how HER2-targeted agents can be incorporated into the management of patients with CRC
    • Outline how the multidisciplinary team can support patients with HER2+ CRC
    Colorectal Cancer, Gastrointestinal Cancers
    Watch Time: 34 mins
    touchPANEL DISCUSSION
    What are the implications of the latest data for HER2-targeted therapies in HER2-tested patients with colorectal cancer?
    CE/CME ACCREDITED Dr Ian Chau, Dr Antonia Sepulveda, Dr Silvia Marsoni

    Watch three experts discuss testing and treatment guidelines for HER2+ colorectal cancer (CRC) and clinical trial data for HER2-targeted therapies.

    Learning objectives
    Learning Objectives
    • Explain the testing methods used to identify patients with human epidermal growth factor receptor 2-positive (HER2+) colorectal cancer (CRC) and the interpretation of the results
    • Summarize the current guidelines for managing patients with HER2+ CRC
    • Discuss the recent efficacy and safety data for HER2-targeted agents in CRC
    Lung Cancer, Colorectal Cancer
    Watch Time: 30 mins
    touchTALKS
    Investigating KRASG12C inhibitors: How might they improve outcomes for patients with solid tumours?
    Prof. Tony Mok Translations available:

    Prof. Tony Mok discusses the role of KRAS mutations in solid tumours and the impact of KRASG12C inhibitors on patient outcomes.

    Learning objectives
    Learning Objectives
    • Describe the role of KRAS in tumourigenesis and the implications of the KRASG12C mutation for patients with solid tumours
    • Evaluate the efficacy and safety of KRASG12C inhibitors in advanced and metastatic KRAS-mutated solid tumours
    • Formulate strategies to overcome intrinsic or acquired resistance to KRASG12C-directed therapies
    Colorectal Cancer
    Treatment Options in BRAF-mutant Metastatic Colorectal Cancer
    Marco Cefali, Maria Celeste Palmarocchi, Sara De Dosso

    touchREVIEWS in Oncology & Haematology. 2022;18(2):103-6 DOI: https://doi.org/10.17925/OHR.2022.18.2.103

    Until recently, treatment options for metastatic colorectal cancer (CRC) have been limited to a cytotoxic chemotherapy with or without an anti-epithelial growth-factor receptor (EGFR) monoclonal antibody, namely cetuximab and panitumumab, or an anti-angiogenic agent such as bevacizumab, aflibercept or ramucirumab. For subsequent lines of treatment, the tyrosine kinase inhibitor regorafenib is an important part of […]

    Colorectal Cancer
    Developed by Touch
    Benjamin Weingberg, ASCO 2022: Highlights of ASCO in colorectal cancer, dostarlimab and the DYNAMIC study
    Watch Time: 8 mins

    Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the highlights of colorectal cancer at ASCO 2022. A subset of colorectal cancer is mismatch repair deficient and is responsive to PD-1 blockade in the metastatic setting. This led to the phase II study where dostarlimab, an anti PD-1 monoclonal antibody, was administered to patients with […]

    Colorectal Cancer
    Developed by Touch
    Benjamin Weingberg, ASCO 2022: Highlights of ASCO in colorectal cancer, the PARADIGM study
    Watch Time: 3 mins

    PARADIGM is the first prospective trial to examine panitumumab versus bevacizumab in colorectal cancer. Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the findings of the phase III PARADIGM study in patients with RAS wild-type (WT) metastatic colorectal cancer. The abstract entitled ‘Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment […]

    Colorectal Cancer
    Developed by Touch
    Takayuki Yoshino, ASCO 2022: PARADIGM trial of panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with MCRC
    Watch Time: 3 mins

    Dr Takayuki Yoshino (National Cancer Center Hospital East, Chiba, Japan) discusses the findings from the phase 3 PARADIGM trial, which was part of a plenary session and selected as one of the top abstracts from the conference. The trial assessed panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type […]

    Colorectal Cancer
    Developed by Touch
    Takayuki Yoshino, ASCO 2022: The impact of tumour location on prognosis in metastatic colorectal cancer
    Watch Time: 3 mins

    Dr Takayuki Yoshino (National Cancer Center Hospital East, Chiba, Japan) discusses the findings from the phase 3 PARADIGM trial, which was part of a plenary session and selected as one of the top abstracts from the conference. The trial assessed panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72